Escherichia coli H10407 demonstrated low '25I-human lactoferrin (IlLf) binding (7%) and was insusceptible to group A (A, El, E2, E3, E6, and K) and group B (B, D, Ta, Ib, and V) colicins. Conversely, a spontaneous HLf high-binding (44%) variant, H10407(Lf), demonstrated an increased susceptibility to both colicin groups.Colicin-insusceptible E. coli wild-type strains 75ColT, 84ColT, and 98lColT showed a low degree of HLf binding, i.e., 4, 8, and 10%, respectively. The HLf binding capacity was high in the corresponding colicin-susceptible mutants 75ColS (43%), 84ColS (32%), and 981ColS (43%). Furthermore, HLf low-(<5%) and high-(>35%) binding E. coli clinical isolates (10 in each category) were tested for susceptibility against 11 colicins. Colicin V susceptibility did not correlate with HLf binding in either categories. However, with the remaining colicins, three distinct HLf-binding, colicin susceptibility patterns were observed; (i) 10 of 10 HLf low-binding strains were colicin insusceptible, (ii) 6 of 10 HLf high-binding strains were also colicin insusceptible, and (iii) the remaining HLf high binders were highly colicin susceptible. Certain proteins in the cell envelope and outer membrane of wild-type H10407 (HLf low binder, colicin insusceptible) showed a lower mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis compared to the corresponding proteins of mutant H10407(Lf) (HLf high binder, colicin susceptible). These mobility differences were also associated with HLf-binding proteins in Western blot (ligand blot) analysis. The wild type showed a smooth form of lipopolysaccharide (LPS) with a distinct ladder of 0-chains, compared to the rough LPS of the mutant.Exogenous smooth LPS from wild-type H10407 inhibited 125T-HLf binding to mutant H10407(Lf) in a dose-dependent manner, while rough LPS was ineffective. These data establish a correlation between HLf binding and colicin susceptibility in E. coli. The LPS seems to be associated with the HLf binding components and the colicin receptors in a similar manner and interferes with the interaction of these eucaryotic and procaryotic antimicrobial agents with E. coli.